Alprostadil Cream: Uses, Dosage, and Side Effects

Alprostadil cream is a topical treatment for erectile dysfunction that delivers a synthetic form of prostaglandin E1 directly to the penile tissue, prompting increased blood flow and erection. Marketed under brand names like Vitaros and Virirec in countries where it is approved, the cream occupies a unique niche: it works locally rather than systemically, which gives it a different side-effect profile than oral medications. Its regulatory journey has been uneven, though, with approvals in Canada, parts of Europe, Latin America, and the Middle East, but repeated rejections by the U.S. FDA.

How Alprostadil Cream Works

Alprostadil is a synthetic version of prostaglandin E1 (PGE1), a naturally occurring fatty-acid compound your body already uses to regulate blood flow and inflammation. When applied to the tip of the penis, the drug binds to PGE1 receptors on smooth muscle cells in penile blood vessels. That binding triggers a chain of events inside the cell that ultimately relaxes the smooth muscle lining those vessels, allowing them to widen and fill with blood, which produces an erection.¹ The cream formulation includes a permeation enhancer called DDAIP (dodecyl 2-N,N-dimethylaminopropionate), which helps the drug cross the skin of the glans penis and reach the underlying vascular tissue. Without that enhancer, the active ingredient would mostly sit on the surface without being absorbed effectively.

Because the drug acts locally, very little reaches the broader bloodstream. This is a key distinction from oral ED medications, which circulate through the entire body before reaching penile tissue. The localized action means alprostadil cream is poorly absorbed into the systemic circulation, which reduces the likelihood of body-wide side effects like headaches, flushing, or changes in blood pressure that are common with oral alternatives.²

How Well Does It Actually Work?

Clinical trials have tested alprostadil cream against placebo in men with varying degrees of erectile dysfunction, and the results consistently show meaningful improvement. A systematic review and meta-analysis found that the topical form of alprostadil improved scores on the International Index of Erectile Function (a widely used questionnaire) by about 4.7 points compared to placebo.³ In individual trials, improvements from baseline have been reported as high as 13 points on the erectile function subscale, which represents a clinically significant change for most men.⁴

Those numbers deserve some context. The erectile function subscale runs from 1 to 30, with scores below 25 generally indicating some degree of dysfunction. A 5-point bump can be the difference between finding intercourse difficult and finding it satisfactory. A 13-point gain, seen in some trials, moves men from moderate dysfunction well into the normal range. That said, the meta-analysis flagged high variability between individual studies, so results will differ from person to person.

How the cream is applied also matters for outcomes. A crossover trial compared the standard application method to an intra-meatal technique, where the cream is placed just inside the urethral opening at the tip of the penis rather than on the outer surface alone. The intra-meatal method produced better erectile function scores and a significantly higher rate of successful penetration attempts.⁵ Patients also reported greater satisfaction with the intra-meatal approach. This suggests that where you place the cream, not just whether you use it, can meaningfully affect how well it works.

Dosage and Application

Alprostadil cream is typically supplied in single-use applicators containing either 200 or 300 micrograms of the active ingredient. The 300 mcg dose is the more commonly prescribed strength for most men with erectile dysfunction, though physicians sometimes start with the lower dose to gauge tolerability. The cream is applied to the tip of the penis (the meatus and surrounding glans) about 5 to 30 minutes before anticipated sexual activity. Onset of effect varies, but many men notice the beginnings of a response within 5 to 15 minutes, considerably faster than the 30-to-60-minute wait typical with oral ED medications.

A few practical tips make the application smoother. The area should be dry before applying. The cream should be gently rubbed in to aid absorption rather than simply deposited as a blob. Men who use condoms should note that the cream’s permeation enhancer may weaken latex, so polyurethane condoms are the recommended alternative. The cream should not be used more than once in a 24-hour period, and it is not designed for daily use in the way some low-dose oral ED medications are.

Common Side Effects

The most frequently reported side effects are localized to the application site. Penile pain and redness (erythema) are the most common complaints, appearing in a substantial minority of users.³ These effects are typically mild to moderate and wear off on their own within an hour or so. Some men also report a warm or burning sensation at the application site, which is partly the permeation enhancer doing its job and partly the vasodilatory effect of the drug itself.

Other localized effects can include:

Itching: a mild prickling or itch at the glans that usually resolves quickly.
Swelling: slight edema of the glans, which typically subsides within an hour.
Prolonged erection: rare, but any erection lasting more than four hours requires medical attention, just as with any other ED treatment.

Across clinical trials, these localized side effects have been described as mild to moderate and transient, meaning they resolve without intervention and do not tend to worsen with repeated use.⁴ Most men who experience them continue using the product rather than discontinuing.

Systemic Side Effects and Safety

One of alprostadil cream’s selling points is that body-wide side effects are uncommon. Because the drug stays largely at the application site, systemic adverse events have been reported in only about 3% of treated patients in clinical studies.² This is a meaningfully lower rate of systemic effects than what is seen with oral PDE5 inhibitors, which commonly cause headaches, nasal congestion, facial flushing, and occasionally vision changes.

That 3% figure is reassuring, but it does not mean zero risk. Men taking blood-thinning medications should be cautious, since alprostadil has antiplatelet properties that could theoretically amplify bleeding tendency. Men with conditions that predispose them to priapism, such as sickle cell disease, should use the cream only under close medical supervision. And while the cream does not interact with nitrate medications in the dangerous way that PDE5 inhibitors do, it is still wise to discuss your full medication list with a prescriber before starting.

Effects on Sexual Partners

A question many couples have but may not think to ask their doctor: does the cream affect the partner during intercourse? It can. In a long-term safety study, the most common partner complaint was vaginal burning or itching, reported by about 2% of female partners.⁶ The active drug and especially the DDAIP permeation enhancer can transfer to vaginal or other mucosal tissue during sexual contact, causing mild irritation.

Using a condom eliminates the issue for most couples, with the caveat about latex mentioned earlier. Some prescribers suggest waiting until the cream has been fully absorbed before intercourse to reduce transfer, though this can be a tricky balance since the drug works best when it has not been entirely wiped away. If a partner experiences persistent irritation, switching to barrier protection or discussing alternative treatments is reasonable.

Who Is a Good Candidate for Alprostadil Cream?

Alprostadil cream fills a gap in the treatment ladder for erectile dysfunction. First-line therapy for most men is an oral PDE5 inhibitor like sildenafil or tadalafil, which works well for a majority but fails or causes intolerable side effects in roughly a third of users. When oral medications are not an option, the traditional second-line step has been penile injections (intracavernosal alprostadil) or a urethral suppository. These are effective but come with obvious downsides: many men are understandably reluctant to inject their penis, and compliance with injection therapy tends to drop off significantly over time because of its invasive nature.⁴

The cream slots in between these options as a non-invasive, locally acting alternative that avoids the systemic side effects of pills and the discomfort of needles. Men who are good candidates typically include:

Those who cannot take PDE5 inhibitors: men on nitrate medications for heart disease, for instance, who face dangerous blood-pressure drops if they use sildenafil or similar drugs.
Men who have tried oral medications without success: the cream uses an entirely different pharmacological pathway, so it can work when PDE5 inhibitors don’t.
Those who find injections unacceptable: the cream offers a second-line option without needles.
Men who want a fast-acting option: onset in as little as 5 minutes appeals to those who find the planning required for oral drugs inconvenient.

Men with severe vascular damage to the penis (such as from advanced diabetes or post-surgical nerve injury) may find that the cream is insufficient on its own, since it depends on there being enough intact vascular tissue to respond to vasodilation. For this group, injection therapy or a vacuum device may still be necessary.

Where You Can Get It and Where You Cannot

Alprostadil cream’s availability depends heavily on where you live. The product has been approved in Canada, Mexico, and a number of European, Latin American, and Middle Eastern countries under the brand names Vitaros and Virirec. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) has evaluated it and it is available on prescription through the NHS.⁷

In the United States, however, the FDA has rejected the cream’s application twice over the span of a decade, issuing complete response letters indicating that the agency could not approve it in its submitted form.⁸ The specific reasons behind the rejections have not been fully disclosed publicly, but they are generally understood to involve manufacturing and formulation concerns rather than doubts about the drug’s efficacy or safety. For American men, this means the topical cream remains unavailable through standard prescribing channels, even though the injectable and urethral suppository forms of alprostadil have long been FDA-approved.

Some U.S. compounding pharmacies prepare their own topical alprostadil formulations, but these are not identical to the commercially manufactured product. Compounded versions may vary in the permeation enhancer used, concentration accuracy, and overall consistency, so their effectiveness and safety profile can differ. If you are considering a compounded version, having a frank conversation with the prescribing physician about these limitations is worthwhile.

Cost Compared to Oral Medications

Where it is available, alprostadil cream is not cheap relative to the most common ED treatment. In the UK, a single dose of the cream runs about £10, while generic sildenafil tablets cost between roughly £0.28 and £0.31 per dose depending on strength.⁷ That is more than thirty times the price per use. The cream is slightly less expensive per dose than injectable alprostadil or the urethral suppository form, so for men who specifically need alprostadil rather than an oral PDE5 inhibitor, the cream is the most affordable delivery route for that molecule.

The cost picture shifts depending on insurance coverage and the healthcare system in your country. In the UK’s NHS, prescriptions for ED treatment are limited to certain qualifying conditions (such as diabetes, prostate surgery, or severe distress), and the cream is available under those criteria. In countries without universal coverage, the out-of-pocket cost can add up quickly for a treatment used several times per month. This financial reality is one reason the cream is generally positioned as a second or third option rather than a first-line therapy for most men.

Research in Female Sexual Arousal Disorder

An area of research that may surprise readers involves alprostadil cream for women. Because the drug works by increasing blood flow to mucosal tissue, researchers have tested whether topical application to the vulva and clitoris could improve genital arousal in women diagnosed with female sexual arousal disorder. A proof-of-concept study in 10 women found that alprostadil cream produced a statistically significant increase in genital temperature (a physiological marker of arousal) compared to a standard lubricant. The effect appeared first on the vulva within about 9 minutes and on the clitoris within about 19 minutes.⁹

A larger placebo-controlled trial in Chinese women tested three doses of alprostadil cream (500, 700, and 900 mcg) and found that arousal success rates increased in a dose-dependent manner. Women using the highest dose reported successful arousal about 54% of the time, compared to about 33% for placebo. The same pattern held for scores on a standardized female sexual function questionnaire, with the highest dose group showing roughly a 23% improvement from baseline compared to about 15% for placebo.¹⁰

This research remains in relatively early stages, and no topical alprostadil product has been approved for women anywhere in the world. The findings are interesting because effective treatments for female arousal disorder are scarce, and the mechanism of increased genital blood flow is plausible. But turning proof-of-concept data into an approved therapy typically requires larger trials, long-term safety data, and a manufacturer willing to fund the regulatory process. For now, the female application remains a research curiosity rather than a clinical option.

How It Compares to Penile Injections

Since alprostadil cream and alprostadil injections use the same active drug, comparing them is instructive. Injectable alprostadil (brand name Caverject) is delivered directly into the corpora cavernosa of the penis using a fine needle. It is highly effective, producing erections adequate for intercourse in a large majority of users, and works even in men with severe ED who do not respond to oral therapy.

The cream trades some of that potency for comfort and simplicity. It does not require self-injection, which is a deal-breaker for many men, and it avoids the injection-specific risks of penile scarring, fibrosis, and hematoma. The meta-analysis comparing routes of alprostadil delivery confirmed that both topical and intraurethral forms produce statistically significant improvement in erectile function compared to placebo, though the intraurethral form showed a particularly strong pooled odds ratio for improvement.³ In practice, this means the cream is a reasonable starting point for men stepping beyond oral therapy, with injections held in reserve for those who need a stronger intervention.

The compliance difference is worth emphasizing. Long-term studies of penile injection therapy consistently show high dropout rates, with many men eventually abandoning the treatment. Fear of needles, injection-site pain, and the perceived unnaturalness of the process all contribute. The cream, being painless to apply and non-invasive, has a more favorable adherence profile in practice, which matters because a treatment only works if people actually use it.

1
Research and Reports in Urology. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review
2
PubMed Central. Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience
3
PubMed Central. The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta-analysis
4
PubMed Central. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review
5
PubMed. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial
6
PubMed. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction
7
National Institute for Health and Care Excellence. Erectile dysfunction: Alprostadil cream
8
HCPLive. FDA Rejects Apricus Biosciences’ Alprostadil Erectile Dysfunction Cream
9
PubMed Central. Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation
10
PubMed. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study in chinese population